These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 16718875)
1. Report from the 13th retrovirus conference. Integrase inhibitors on the way. Hicks CB AIDS Clin Care; 2006 Apr; 18(4):33-4. PubMed ID: 16718875 [No Abstract] [Full Text] [Related]
2. XVI International AIDS Conference. New drug classes from Toronto. Plus some older ones. Sharp M Posit Aware; 2006; 17(6):16-7. PubMed ID: 17233084 [No Abstract] [Full Text] [Related]
3. Anti-HIV agents. Raltegravir (Isentress)--results after one year. TreatmentUpdate; 2007; 19(6):8-9. PubMed ID: 18041152 [No Abstract] [Full Text] [Related]
4. Report from the XVI International AIDS Conference. Integrase inhibitors. Hicks CB AIDS Clin Care; 2006 Nov; 18(11):101. PubMed ID: 17183747 [No Abstract] [Full Text] [Related]
6. International AIDS Conference: Toronto. Proj Inf Perspect; 2006 Oct; (42):4-11. PubMed ID: 17162805 [No Abstract] [Full Text] [Related]
7. [Integrase inhibition--a new mode of action in HIV therapy]. van Lunzen J; Degen O MMW Fortschr Med; 2008 Apr; 150 Spec No 1():64-7. PubMed ID: 19031567 [No Abstract] [Full Text] [Related]
8. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. GSK572--a "next generation" integrase inhibitor? Hicks CB J Watch AIDS Clin Care; 2009 Oct; 21(10):80-1. PubMed ID: 20461843 [No Abstract] [Full Text] [Related]
9. HIV integrase inhibitors show potent activity in clinical trials. Winslow DL AIDS Alert; 2007 Jan; 22(1):10-1. PubMed ID: 17722343 [No Abstract] [Full Text] [Related]
10. Two studies show Kaletra and Isentress similarly suppress HIV, yet have different side effects. Proj Inf Perspect; 2009 Mar; (48):6. PubMed ID: 19492458 [No Abstract] [Full Text] [Related]
11. Report from the 16th Conference on Retroviruses and Opportunistic Infections. SWITCHMRK: an avoidable raltegravir disaster. Albrecht H J Watch AIDS Clin Care; 2009 Apr; 21(4):30-1. PubMed ID: 19548330 [No Abstract] [Full Text] [Related]
12. Report from the 15th Retrovirus Conference. Parsing the options from comparative trials of initial antiretroviral therapy. Feinberg J AIDS Clin Care; 2008 Apr; 20(4):27. PubMed ID: 19256087 [No Abstract] [Full Text] [Related]
14. [Integrase inhibitor in HIV therapy. Does dolutegravir set new standards?]. MMW Fortschr Med; 2014 Jun; 156 Suppl 1():58-9. PubMed ID: 25026862 [No Abstract] [Full Text] [Related]
15. Report from the 13th retrovirus conference. Treatment interruption, interrupted. Henry K AIDS Clin Care; 2006 Apr; 18(4):35-6. PubMed ID: 16718878 [No Abstract] [Full Text] [Related]
16. [Raltegravir - long lasting effectiveness, well tolerated and well combined]. MMW Fortschr Med; 2013 Jun; 155 Suppl 1():30-1. PubMed ID: 23961651 [No Abstract] [Full Text] [Related]
17. HIV integrase inhibitors--out of the pipeline and into the clinic. Havlir DV N Engl J Med; 2008 Jul; 359(4):416-8. PubMed ID: 18650518 [No Abstract] [Full Text] [Related]
18. Study supports use of Isentress for first line treatment. Proj Inf Perspect; 2008 Dec; (47):9. PubMed ID: 19227560 [No Abstract] [Full Text] [Related]
19. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. Cooper DA; Steigbigel RT; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Teppler H; Nguyen BY; N Engl J Med; 2008 Jul; 359(4):355-65. PubMed ID: 18650513 [TBL] [Abstract][Full Text] [Related]
20. Integrase inhibitors in the treatment of HIV-1 infection. Powderly WG J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]